M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical Business ReviewThe acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Business Review The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. M&A / DealsRead full story Post navigation Previous: Adcendo secures $75m in Series C funding for ADC developmentNext: Lilly to acquire CrossBridge Bio for up to $300m Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026